A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

Phase 1 Completed 32 enrolled ArQule, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the safety, tolerability and recommended Phase 2 dose of ARQ 197 when administered in combination with erlotinib to patients with advanced solid tumors

Timeline

Start: 2008-02
Primary completion: 2010-09
Completion: —

Publications

Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 2012 Dec 1;118(23):5903-11. doi: 10.1002/cncr.27575. Epub 2012 May 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tivantinib	Small molecule	120 mg	Oral
Subject	Tivantinib	Small molecule	240 mg	Oral
Subject	Tivantinib	Small molecule	360 mg	Oral
Subject	Tivantinib	Small molecule	480 mg	Oral
Background	Erlotinib	Small molecule	150 mg	—

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications